Plasma plasminogen activator inhibiter-1, tissue-type plasminogen activator and tissue-type plasminogen activator/plasminogen activator inhibiter-1 in hypertensive patients

CLINICAL FOCUS ›› 2008, Vol. 23 ›› Issue (20): 1455-1457.

Previous Articles Next Articles

Plasma plasminogen activator inhibiter-1, tissue-type plasminogen activator and tissue-type plasminogen activator/plasminogen activator inhibiter-1 in hypertensive patients

MA Yan;XU Xiu-ying

Online:2008-10-20 Published:2008-10-20

Abstract

CLC Number:

R544.1

MA Yan;XU Xiu-ying. Plasma plasminogen activator inhibiter-1, tissue-type plasminogen activator and tissue-type plasminogen activator/plasminogen activator inhibiter-1 in hypertensive patients[J]. CLINICAL FOCUS, 2008, 23(20): 1455-1457.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/

https://huicui.hebmu.edu.cn/EN/Y2008/V23/I20/1455

[1]	Liu Yi, Cui Kun, Liu Chang, Zhao Haotian, Li Li, Xue Hongyuan. Correlation between serum secreted frizzled-related protein 5 and early renal damage in patients with essential hypertension [J]. Clinical Focus, 2023, 38(12): 1073-1077.
[2]	Jiang Ji, Zhu Xiaogang, Jiang Shan, Dawa Zhaba, Cen Qiang. Risk factors of proteinuria in hypertensive people living at high altitude for generations [J]. Clinical Focus, 2023, 38(12): 1086-1090.
[3]	Xu Yang, Xue Ling. Influencing factors for mild cognitive impairment in type H hypertension patients combined with type 2 diabetes mellitus [J]. Clinical Focus, 2023, 38(10): 887-892.
[4]	. [J]. Clinical Focus, 2023, 38(2): 181-184.
[5]	. [J]. Clinical Focus, 2023, 38(1): 88-92.
[6]	Yin Yikun, Yin Xunwei, Wang Jialin, Sun Junzhi. Impacts of Tai Chi exercise cycle on blood pressure and cardiovascular risk factors in essential hypertension: a systematic review and meta-analysis [J]. Clinical Focus, 2022, 37(7): 599-606.
[7]	An Qinyan, Jiang Rong, Kang Bin, Du Ming, Zhou Renming, Zhao Hongjuan, Duan Yi, Lu Fei, Liu Jinming. Levels and clinical significance of RDW, NT-proBNP, BigET-1, HMGB1 in patients with idiopathic pulmonary arterial hypertension [J]. Clinical Focus, 2021, 36(11): 1001-1004.
[8]	. [J]. Clinical Focus, 2021, 36(8): 744-748.
[9]	Gong Tao, Hu Yueyuan, Gao Yun, Guo Chang, Shen Huinan, Wang Dongyu. Relationship between H-type hypertension and severity of neurological deficit in early acute cerebral infarction of LAA [J]. Clinical Focus, 2021, 36(7): 612-615.
[10]	. [J]. Clinical Focus, 2021, 36(6): 566-568.
[11]	. [J]. Clinical Focus, 2021, 36(3): 270-276.
[12]	Liu Xiaoteng, Shan Weichao, Hou Ruitian, Lin Jinping, Gao Yu, Jin Fengbiao, Liu Chang. Correlation between serum hypersensitive C-reactive protein, lipoprotein-related phospholipase A₂and senile essential hypertension complicated with type 2 diabetes [J]. Clinical Focus, 2021, 36(1): 25-29.
[13]	Liang Yuling, Li Wenxi, Gu Xuewen. Randomized controlled trial of Tianma Gouteng Decoction and irbesartan in treatment of essential hypertension [J]. Clinical Focus, 2020, 35(12): 1097-1100.
[14]	Zhu Bin;Wang Yongxia. Correlation between carotid plaque and blood pressure variation in patients with hypertension [J]. Clinical Focus, 2015, 30(12): 1360-1362.
[15]	Quan Feng;Fan Xuemei;Fang Wenlong. Clinical study of systemic lupus erythematosus associated pulmonary hypertension [J]. Clinical Focus, 2015, 30(12): 1402-1.40414e+007.

Plasma plasminogen activator inhibiter-1, tissue-type plasminogen activator and tissue-type plasminogen activator/plasminogen activator inhibiter-1 in hypertensive patients

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments